Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2003
11/20/2003WO2002034915A3 Preferred segments of neural thread protein and methods of using the same
11/20/2003WO2002033050A8 Methods and compositions for promoting the maturation of monocytes
11/20/2003WO2002032869A8 Substituted heterocyclic compounds for treating multidrug resistance
11/20/2003WO2002028861A8 Methods and compounds for treating proliferative diseases
11/20/2003WO2002016407A3 Sh2 domain binding inhibitors
11/20/2003US20030216586 Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them
11/20/2003US20030216574 Pyrazine based inhibitors of glycogen synthase kinase 3
11/20/2003US20030216559 Medical diagnosis using polypeptide; amplification, determination, calibration; monitoring immunotherapy
11/20/2003US20030216558 Novel compositions and methods for cancer
11/20/2003US20030216546 Genetically engineered fusion proteins for use in diagnosis and treatment of cancer, viral infections, autoimmune and alloimmune diseases
11/20/2003US20030216481 Cyclooxygenase inhibitors; osteoarthritis, rheumatoid arthritis, and other injuries that result from overuse
11/20/2003US20030216468 Thiol-based NAALADase inhibitors
11/20/2003US20030216462 Anticancer agents; psoriasis
11/20/2003US20030216460 N3 alkylated benzimidazole derivatives as MEK inhibitors
11/20/2003US20030216454 Thiazolidine-4-one derivative, method for preparing the same, and pharmaceutical composition containing the same
11/20/2003US20030216446 Aryl ureas as kinase inhibitors
11/20/2003US20030216440 Process for preparing arylacetylaminothiazoles
11/20/2003US20030216437 Thrombin receptor antagonists
11/20/2003US20030216436 Potent, simplified derivatives of immunosuppressive agents
11/20/2003US20030216432 Non-insulin sensitive diabetes; anticancer agents ; therapy, medical diagnosis
11/20/2003US20030216430 3, 4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
11/20/2003US20030216429 7-Heterocyclyl quinoline and thieno[2,3-b]pyridine derivatives useful as antagonists of gonadotropin releasing hormone
11/20/2003US20030216428 Sexual disorders; blood disorders; osteoporosis; bone disorders
11/20/2003US20030216425 Tricyclic compounds as mrp1-inhibitors
11/20/2003US20030216421 Cascade esters of camptothecins and methods of treating cancer using these compounds
11/20/2003US20030216419 Isomeric fused pyrrolocarbazoles and isoindolones
11/20/2003US20030216417 Substituted anilino-quinoline compounds and use thereof
11/20/2003US20030216416 Novel crystalline of n-[4-[2-(2-amino-4,7-dihydro-4oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and process therefor
11/20/2003US20030216410 Administering to a cancer patient an indole-2-one derivative containing pyrrole ring as protein kinase inhibitor together with a cyclooxygenase inhibitor to treat the cancer
11/20/2003US20030216406 Pyrimidine derivatives
11/20/2003US20030216404 Hydroxamic acid derivatives
11/20/2003US20030216397 A compound having a fused ecteinascidin five ring system with a 1,4 bridge; anticarcinogenic agent
11/20/2003US20030216396 An urea compounds containing a pyridine, quinoline, or isoquinoline functionality, which are useful in the treatment of cancer, inflammation, osteoporosis and angiogenesis
11/20/2003US20030216392 Aryl or heteroaryl substituted ethylcarbonylsulfonamide derivatives used as inhibitors of neutrophils chemotaxis and degranulation induced by interleukin 8
11/20/2003US20030216391 Oxazole or thiazole-ethyl-oxy-indane acetic acid derivatives; useful for the treatment of diseases such as diabetes, obesity, hyperlipidemia and atherosclerosis
11/20/2003US20030216389 Therapeutic morpholino-substituted compounds
11/20/2003US20030216388 Cyclocarbamate derivatives as progesterone receptor modulators
11/20/2003US20030216381 Can bind to Prostaglandin E2 receptors, especially, EP3 receptor and/or EP4 receptor and show antagonizing activity, and may be useful for prevention and/or treatment of disease, for example, pain, allergy, Alzheimer's disease, cancer
11/20/2003US20030216375 Sulfonamide substituted diphenyl thiourea compounds; use thereof in treating IL-8, GRO alpha, GRO beta, GRO gamma, NAP-2, and ENA-78 mediated diseases
11/20/2003US20030216369 Administering compounds which inhibit heat shock protein 90 proteins; methods block Rb negative or deficient cells in the G2/M phase of the cell cycle and rapidly causes their destruction
11/20/2003US20030216362 Estra-1,3,5 (10)-triene derivatives
11/20/2003US20030216359 Administering vitamin D or a derivative and a cytotoxic agent or a glucocorticoid and, optionally, a bisphosphonate
11/20/2003US20030216356 Cause the selective destruction of tumour vasculature; are used to inhibit and/or reverse, and/or alleviate symptoms of angiogenesis
11/20/2003US20030216354 Prepared from Penicillium sp.; treatment of plasmodia, trypanosomes and carcinosis.
11/20/2003US20030216335 Treating endometriosis by contacting the subject with a nucleic acid that modulates the expression of VEGF, VEGFR1, and/or VEGFR2
11/20/2003US20030216333 Antisense modulation of glycogen synthase kinase3 alpha expression
11/20/2003US20030216317 Protein having cell-recognizing activity and/or cytocidal activity
11/20/2003US20030216316 Pharmaceutical compositions comprising erythropoietin for treatment of cancer
11/20/2003US20030216315 Modulation of immune response by non-peptide binding stress response polypeptides
11/20/2003US20030215921 Vascular endothelial growth factor-2
11/20/2003US20030215898 Methods for using 22045, a human cyclic nucleotide phosphodiesterase
11/20/2003US20030215895 Immunoglobulin for diagnosing and prognosticating human cancer
11/20/2003US20030215852 Novel pancortin-Pablo protein interactions and methods of use thereof
11/20/2003US20030215829 Nuclear hormone receptors
11/20/2003US20030215822 Comprises nucleotide sequences coding polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune/inflammatory, cardiovascular, neurological and developmental disorder
11/20/2003US20030215803 Isolated polynucleotide which hybridizes to given sequence; use in diagnosing cancer and for inhibiting tumor growth
11/20/2003US20030215523 Medicinal compositions for concomitant use as anticancer agent
11/20/2003US20030215496 Solid carrier includes a hydrophililc surfactant and a drug
11/20/2003US20030215492 Administering a mammalian host for treating a disease caused by proliferation of eukaryotic cells a formulation containing a complex of lipid and a drug 7-ethyl-10-hydroxycamptothecin
11/20/2003US20030215489 Chemosensitizing with liposomes containing oligonucleotides
11/20/2003US20030215467 Isolated from resected and washed human gastrointestinal tract; for oral administration; probiotics
11/20/2003US20030215460 Methods and compositions for inducing an immune response
11/20/2003US20030215457 Comprising a nucleic acid, a polypeptide encoded by the nucleic acid, and a compound, preferably an antibody or fragment thereof, that binds to the polypeptide, preferably binding to the extracellular domain of LIV-1 polypeptide
11/20/2003US20030215452 Methods and compositions for treating hematological disorders using 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 or 13249 molecules
11/20/2003US20030215451 In treatment (including prevention) or identification of a human subject at risk of tissue damage, preferably liver or heart tissue damage
11/20/2003US20030215450 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
11/20/2003US20030215447 Produced by hybridoma cell line DSM ACC 2533
11/20/2003US20030215443 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
11/20/2003US20030215429 Lyophilised or sonicated Lactobacillus bacteria, grampositivie bacteria, gramnegative bacteria; antitumor agents, therapeutic treatment of autoimmune diseases, gastrointestinal disorders, nervodegenerative diseases
11/20/2003US20030215388 Can be administered in conjunction with radiation or chemotherapeutic agents.
11/20/2003US20030213920 Methods for sterilizing preparations containing albumin
11/20/2003CA2492044A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
11/20/2003CA2485655A1 Recombinant fowlpox virus
11/20/2003CA2485527A1 Substituted pyrroline kinase inhibitors
11/20/2003CA2485431A1 Platinum complexes having antitumor activity
11/20/2003CA2485400A1 Methylated immunostimulatory oligonucleotides and methods of using the same
11/20/2003CA2485373A1 Epha2 monoclonal antibodies and methods of use thereof
11/20/2003CA2485256A1 Pathogen vaccines and methods for using the same
11/20/2003CA2485252A1 Methods of using thiazolidine derivatives to treat cancer or inflammation
11/20/2003CA2485083A1 Hexahydro-pyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and preparation methods thereof
11/20/2003CA2484835A1 Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process
11/20/2003CA2484815A1 Cascade esters of camptothecins and methods of treating cancer using these compounds
11/20/2003CA2484607A1 Methods and compositions for inducing an immune response
11/20/2003CA2484398A1 Method for reducing pain using oncolytic viruses
11/20/2003CA2484266A1 Cancer vaccines and methods of using the same
11/20/2003CA2484144A1 Eif-5a nucleic acids for inhibiting apoptosis
11/20/2003CA2483991A1 Substantially pure solid form of the enol tautomer of 3-indolylpyruvic acid for use in the treatment of central nervous system disturbances
11/20/2003CA2480488A1 Novel diazabicyclic biaryl derivatives
11/20/2003CA2462203A1 Methods and products for enhancing immune responses using imidazoquinoline compounds
11/20/2003CA2451081A1 Adenosine a<sb>3</sb> receptor modulators
11/19/2003EP1362911A1 Transgenic animal having drug metabolism enzyme gene and utilization thereof
11/19/2003EP1362868A2 Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R)
11/19/2003EP1362848A1 Process for the preparation of vitamin D derivatives
11/19/2003EP1362601A1 Method of examining effect of angionegesis inhibitor mediated by the inhibition of integrin expression
11/19/2003EP1362598A1 Active oxygen generator containing photosensitizer for ultrasonic therapy
11/19/2003EP1362597A1 Antigenic peptides derived from telomerase
11/19/2003EP1362596A2 Inhibitor of stem cell proliferation and uses thereof
11/19/2003EP1362594A1 Anti-stress agents
11/19/2003EP1362592A1 Use of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-kB
11/19/2003EP1362108A2 Novel human protease and polynucleotides encoding the same
1 ... 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 ... 2211